Board Member
Allogene Therapeutics, Inc. (ALLO)Equibles does not estimate personal net worth.
Get an email with a short summary when Allogene Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get ALLO alertsZachary Roberts, M.D., Ph.D. is recorded as CEO and Board Member at Allogene Therapeutics, Inc. (ALLO) since July 1, 2026. Allogene Therapeutics, Inc. reported in an 8-K filed May 28, 2026 that Zachary Roberts, M.D., Ph.D. was appointed Class I director, effective July 1, 2026. Allogene Therapeutics, Inc. reported in an 8-K filed May 28, 2026 that Zachary Roberts, M.D., Ph.D. was appointed President and Chief Executive Officer, effective July 1, 2026. Zachary Roberts, M.D., Ph.D. has spoken on 1 investor event across 1 company, most recently for Allogene Therapeutics, Inc. on September 9, 2026. Allogene Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Allogene Therapeutics, Inc. includes Geoffrey Parker (CFO), Tim Moore (CTO), Timothy Moore (CTO) and 4 others.
“Effective on the Effective Date, Dr. Roberts was also appointed to the Board as a Class I director, to serve until the Company's 2028 annual meeting of the stockholders and until his successor is duly elected and qualified, or until his earlier death, resignation or removal.”
“On May 28, 2026, the Board of Directors (the "Board") of Allogene Therapeutics, Inc. (the "Company"), upon the recommendation of its Nominating and Corporate Governance Committee, approved the appointment of Zachary Roberts, M.D., Ph.D. as the Company's President and Chief Executive Officer, replacing David Chang, M.D., Ph.D. in such capacities.”
“Beginning with our leading program, we released some data in April from an interim futility analysis. We also are moving very briskly through enrollment in our phase one program, which is a novel therapeutic CAR T-cell product in autoimmune disease indications.”
2026-07-01–present
2026-07-01–present
Biotechnology · Healthcare
CEO, Board Member
2026-07-01–present
